@FierceMedDev: Study: Medtronic next-gen pacer tech achieves atrial fibrillation delay. More | Follow @FierceMedDev
@MarkHFierce: Cardiovascular Systems wants to sell 2.1M shares in a public offering. Simply put: expansion requires funding. Story | Follow @MarkHFierce
@MichaelGFierce: Spoke to MIT's Dr. Robert Langer about drug delivery and nanotech. Story in tomorrow's FierceDrugDelivery report. | Follow @MichaelGFierce
> AtriCure won FDA approval to begin testing its AtriClip device to prevent strokes in patients with atrial fibrillation. Item
> VeriTeQ, a maker of implantable medical devices for identification and radiation dose measurement, has changed its ticker symbol from "DIGAD" to "VTEQ." Item
> TriReme Medical in California said that its Japanese partner, Century Medical, won regulatory approval in Japan for its GliderXtreme PTA catheter to treat peripheral arterial blockages. Item
> Canada's Klox Technologies now has CE mark approval to market its topical photo-converter gel to treat acne vulgaris, a severe form of acne. Item
> Paragonix Technologies has completed a second 510(k) application with the FDA for its device designed for static hypothermic preservation of hearts for transport and eventual transplantation. Item
Biotech News
@FierceBiotech: Gilead charts PhIII success for leukemia drug as J&J showdown awaits. More | Follow @FierceBiotech
@JohnCFierce: Check out my webinar Thursday morning with Toni Ribas and Carol Gallagher on targeted cancer drugs. More | Follow @JohnCFierce
@DamianFierce: AstraZeneca just can't wait to get to Cambridge, plans to deploy 400 scientists to get R&D ball rolling. Story | Follow @DamianFierce
@EmilyMFierce: As resistance rises, one MIT team is investigating how a bacteria-derived toxin could help design new antibiotics. Article | Follow @EmilyMFierce
> Merck spotlights promising data on 'breakthrough' cancer immunotherapy MK-3475. More
> Amgen's cancer-fighting virus boosts melanoma survival in PhIII study. Article
Pharma News
@FiercePharma: Monday's most-read story: Takeda's new outsider CFO charged with $1B cost-cutting plan. More | Follow @FiercePharma
@EricPFierce: Patheon, DSM join forces in $2.6B deal, to create no name company with global reach. More | Follow @EricPFierce
@CarlyHFierce: U.S. approves drug tracking, compound pharmacy oversight law. Story from FiercePharmaManufacturing | Follow @CarlyHFierce
> One certainty: Drug spending will hit $1 trillion in 2014. Story
> EMA: No new safety flags in Roche's stash of unreported side effects. Report
> Philly jury hits J&J with $11M verdict in Topamax birth-defects case. Article
Pharma Manufacturing News
> Glaxo to use new technology in India plant. Report
> 2 Puerto Rico plants up next in Merck job-whacking plan. Story
> J&J, Merck KGaA roll out new China plant projects. Article
> DSM, Patheon join up in $2.6B deal. More
> U.S. approves drug tracking, compound pharmacy oversight law. Story
> Mylan recalls 480,000 bottles of blood pressure med. Item
Biotech Research News
> Tekmira's RNAi antivirals protect animals from lethal doses of Ebola, Marburg. More
> Oxford, MRC Technology team up on migraine drug discovery. Item
> First-ever 'mini-kidney' organs created from human stem cells. Story
> Bacteria-derived toxin could provide design for new antibiotics. Article
> Herb-based compounds improve learning, memory in Alzheimer's mice. News
> Compound that targets fat-burning mechanism discovered. Report